Resource utilisation and treatment costs of an intensified conventional therapy (ICT) with insulin glargine, insulin detemir or NPH insulin in patients with type 1 diabetes;Ressourcenverbrauch und Behandlungskosten unter einer intensivierten konventionellen Therapie (ICT) mit Insulin glargin, Insulindetemir oder NPH-Insulin bei Patienten mit Typ-1-Diabetes

Perfusion

Volumn 23, Issue 3, 2010, Pages 96-103

  Bierwirth, R ^a   Kostev, K ^b   Dippel, F W ^c   Fuchs, S ^b   Kotowa, W ^b  

^a ELISABETH KRANKENHAUS ESSEN   (Germany)

^b IQVIA   (United States)

^c SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Basalinsulin; Cost comparison; Diabetes mellitus type 1; Insulin detemir; Insulin glargine; NPH insulin; Resource utilization

Indexed keywords

GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN;

ADULT; ARTICLE; BODY MASS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE DURATION; DRUG COST; FEMALE; GENERAL PRACTITIONER; GEOGRAPHY; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; NEEDLE; PRESCRIPTION; TREATMENT DURATION;

EID: 77954138957     PISSN: 09350020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Deutsche Diabetes Union (DDU) (Hrsg.). Deutscher Gesundheitsbericht Diabetes 2009. Kirchheim + Co. GmbH, 2008
2. Scherbaum WA, Kerner W (Hrsg.). Evidenzbasierte Leitlinie der DDG - Therapie des Diabetes mellitus Typ 1. Erhältlich unter: http://www.uni-duesseldorf.de/AWMF/ ll/ll-057.htm
3. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
4. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4400 patients observed between 1947 and 1973. Diabetes Care 1978;1:168-188 (Pubitemid 9171570)
5. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993;329:304-309
6. DCCT Research Group. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiocvascular disease in patients with type 1 diabetes. N Engl J Med 2005;353: 2643-2653
7. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-1431
8. Hagenmeyer EG, Koltermann KC, Dippel FW et al. Gesundheitsö konomische Evaluationen zum Vergleich von Insulin glargin mit NPH-Insulin und Insulindetemir in der intensivierten Insulintherapie bei Typ-1- Diabetikern - ein systematischer Review. Poster (P 128/P 128.1) anl. der 45. Jahrestagung der Deutschen Diabetes-Gesellschaft; 12.-15.Mai 2010 in Stuttgart
9. Icks A, Rathmann W, Rosenbauer J et al. Heft 24 - Diabetes mellitus aus der Reihe "Gesundheitsberichterstattung des Bundes". Erhältlich unter: http://www.rki.de
10. Bolli GB, Songini M, Trovati M et al. Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes. Nutr Metab Cardiovasc Dis 2009;19:571-579
11. Mullins P, Sharplin P, Hannele YJ et al. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther 2007;29(8):1607-1618
12. Manini R, Forlani G, Moscatiello S et al. Insulin glargine improves glycemic control and health-related quality of life in type 1 diabetes. Nutr Metab Cardiovasc Dis 2007;17:493-498
13. Ashwell SG, Miel SA Biloust RW et al. Improved glycemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with type 1 diabetes. Diabetic Med 2006;23: 285-292
14. Fulcher GR, Gilbert RE, Yue DK. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Intern Med J 2005;35:536-542
15. Porcellati F, Rossetti P, Pampanelli S et al. Better long-term glycemic control with the basal insulin glargine as compared with NPH in patients with type 1 diabetes mellitus given meal-time lispro insulin. Diabetic Med 2004;21:1213-1220
16. Ratner RE, Hirsch IB, Neifing JL et al. for the U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000;23:639-643
17. Pieber TR, Treichel HC, Hompesch B et al. Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy. Diabetic Med 2007;24:635-642
18. Heller S, Koenen Ch, Bode B. Comparison of insulindetemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallelgroup, treat-to-target noninferiority trial. Clin Therapetics 2009;31(10):2086-2097
19. Becher H, Kostev K, Schröder-Bernhardi D. Validity and representativeness of the "disease analyzer" database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther 2009;47(10):617-626
20. Haas C, Zimmermann L, Höfgen B et al. Internationale Harmonisierung von Arzneimitteltechnologie: Vision und Wirklichkeit. Telemed Proceedings 2008:193-201
21. Brändle M, Azoulay M et al. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 1 and type 2 diabetes in Switzerland. IDF 2009 (Poster)
22. Cameron CG, Bennett HA. Cost-effectiveness of insulin analogues for diabetes mellitus. Can Med Ass J 2009;180(4):400-407
23. Grima DT, Thompson MF et al. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada. Pharmacoeconomics 2007;25(3): 253-266
24. McEwan P, Poole CD et al. Evaluation of the costeffectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UK. Curr Med Res Opin 2007;Suppl 23(1):S7-S19 (Pubitemid 46456917)
25. Warren E, Weatherley-Jones E et al. The clinical and costeffectiveness of long-acting insulin analogue, insulin glargine. Assessment Report, ScHARR Rapid Reviews Group. School of Health and Related Research. University of Sheffield, 2002
26. Warren E, Weatherley-Jones E et al. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol Assess 2004; 8(45):iii,1-57
27. Culyer A, Mc Cabe C, Briggs A et al. Searching for a threshold, not setting one: the role of the national institute of health and clinical excellence. J Health Serv Res Pol 2007;12:56-58
28. Reyes-López A, Lemus-Carmona A et al. Economic analysis of glargine insulin and detemir insulin in patients with type 1 diabetes mellitus in Mexico. 6th ISPOR Annual European Congress 2009. Barcelona, Value in Health 2009;12(7):A221-A460
29. Poole CD, Tetlow T et al. The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: A retrospective database analysis. Curr Med Res Opin 2007;Suppl 23(1):S41-S48 (Pubitemid 46456920)
30. Wiesner T, Schädlich PK, Dippel FW et al. Insulin glargin versus Insulindetemir in der basal-Bolus-Behandlung von Patienten mit Typ-1-Diabetes mellitus. Ökonomische Analyse aus Perspektive der Gesetzlichen Krankenversicherung. Perfusion 2010;23:56-65
31. Silverman SL. From randomized controlled trials to observation Am J Med 2009;6(2):90-97.